Key Points
- Director Garcia Andrea Perez sold 2,500 HIMS shares at an average price of $39.17 for $97,925, trimming her stake by 3.02% to 80,166 shares (worth about $3.14M).
- HIMS shares fell about 1.5% to $37.32 on Thursday with ~2.38M shares traded; the company has an $8.5B market cap, a 52-week range of $23.97–$72.98, and an average analyst target of $45.50 (consensus: Hold).
- Hims & Hers missed quarterly EPS at $0.06 versus a $0.09 estimate while revenue rose 49.2% YoY to $598.98M, and the board approved a $250M share buyback (up to ~3% of shares).
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) Director Garcia Andrea Perez sold 2,500 shares of Hims & Hers Health stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $39.17, for a total value of $97,925.00. Following the completion of the transaction, the director owned 80,166 shares in the company, valued at $3,140,102.22. The trade was a 3.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Hims & Hers Health Trading Down 1.5%
NYSE:HIMS traded down $0.56 on Thursday, hitting $37.32. 2,376,160 shares of the stock were exchanged, compared to its average volume of 31,252,068. The stock has a market cap of $8.50 billion, a PE ratio of 69.35, a PEG ratio of 7.87 and a beta of 2.41. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The stock has a fifty day moving average of $44.65 and a 200-day moving average of $49.39. Hims & Hers Health, Inc. has a fifty-two week low of $23.97 and a fifty-two week high of $72.98.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business's revenue for the quarter was up 49.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.32 earnings per share. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Hims & Hers Health declared that its board has authorized a stock buyback plan on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued.
Analyst Upgrades and Downgrades
HIMS has been the subject of several recent research reports. BTIG Research reiterated a "buy" rating and issued a $85.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. Zacks Research lowered Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. KeyCorp assumed coverage on Hims & Hers Health in a report on Tuesday, October 21st. They set a "sector weight" rating on the stock. Bank of America upped their price target on Hims & Hers Health from $28.00 to $32.00 and gave the stock an "underperform" rating in a report on Tuesday, November 4th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $45.50.
View Our Latest Research Report on Hims & Hers Health
Hedge Funds Weigh In On Hims & Hers Health
A number of institutional investors have recently made changes to their positions in HIMS. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth approximately $26,000. Quent Capital LLC acquired a new stake in Hims & Hers Health in the third quarter valued at $28,000. Binnacle Investments Inc bought a new position in Hims & Hers Health during the 3rd quarter valued at $28,000. Quaker Wealth Management LLC bought a new position in Hims & Hers Health during the 2nd quarter valued at $29,000. Finally, Bessemer Group Inc. grew its holdings in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after acquiring an additional 312 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
